Why the study?
Does universal RV-A vaccination reduce RVGE-related hospitalizations and mortality in young children in Malaysia?
Does universal RV-A vaccination reduce RVGE-related hospitalizations and mortality in young children in Malaysia?
Mathematical modeling suggests that universal rotavirus vaccination would be highly efficacious in reducing RVGE-related hospitalizations and mortality in Malaysia.
May inform Malaysian rotavirus vaccination modeling; leaves open need for prospective effectiveness trials before policy change.
Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published data on RV-A hospitalizations and genotypes, mortality on childhood GE and published genotype-specific efficacy data on two RV-A vaccines. Assuming a 95% vaccine coverage, the overall projected effectiveness was 75.7 to 88.1% for Rotateq and 78.7 to 90.6% for Rotarix® against RVGE-related hospitalizations. The projected annual reduction in RVGE-related deaths was 27 to 32 deaths (from 34 deaths) for Rotateq and 28 to 32 deaths annually for Rotarix. A universal RV-A vaccine is efficacious in reducing RVGE-related hospitalizations and mortality in Malaysia.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: